Clinical and pharmacological differences in early- versus late-onset Parkinson's disease

Movement Disorders : Official Journal of the Movement Disorder Society
G Gomez ArevaloO Gershanik

Abstract

We evaluated whether patients with early-onset Parkinson's disease (EOPD) have a different clinical profile and pharmacological response than those with late-onset disease (LOPD). We performed a retrospective analysis and an acute pharmacological challenge with L-Dopa in 34 EOPD (age at onset between 21 and 40 years) and 34 LOPD (onset after age 60) patients. All patients completed a structured questionnaire cross-checked against medical record charts and underwent an acute levodopa test. Most significant differences were in the mode of onset, time of diagnosis, and degree of initial improvement. We did not observe differences with regard to motor fluctuations. The acute levodopa test showed no differences in latency to response onset between groups. However, the magnitude of the response was greater and the duration shorter in EOPD patients. Younger patients had greater reductions in bradykinesia scores, whereas posture/gait symptomatology was less responsive in older patients. The type and severity of dyskinesias also differed significantly between groups. Our findings suggest that central pharmacokinetics, pharmacodynamics, and possibly, nondopaminergic systems play a role in the age-related differences observed in Parkinson...Continue Reading

References

Mar 1, 1992·Journal of Neurology, Neurosurgery, and Psychiatry·A J HughesA J Lees
Feb 1, 1992·Neurology·R J ElbleL Hughes
Sep 1, 1991·Journal of Neurology, Neurosurgery, and Psychiatry·J BlinY Agid
Jan 1, 1991·Movement Disorders : Official Journal of the Movement Disorder Society·P GiovanniniT Caraceni
Feb 1, 1990·Annals of Neurology·J De KeyserG Vauquelin
Jun 12, 1987·European Journal of Pharmacology·I UshijimaM Yamada
Dec 1, 1987·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·P SeemanW W Tourtellotte
Jan 1, 1987·Movement Disorders : Official Journal of the Movement Disorder Society·N QuinnC D Marsden
Jan 1, 1987·Synapse·P SeemanS Watanabe
Jan 1, 1986·Journal of the Neurological Sciences·J M MayerB Pépin
May 1, 1994·Journal of Neurology, Neurosurgery, and Psychiatry·M RodriguezJ A Obeso
Jan 1, 1993·Journal of Neurology, Neurosurgery, and Psychiatry·R DursoR G Feldman

❮ Previous
Next ❯

Citations

Aug 6, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·W OndoJ Jankovic
Apr 25, 2012·Psychopharmacology·Ilya D Ionov, Nicholas N Severtsev
Mar 3, 2001·Acta Neurologica Scandinavica·H JacobsP Vieregge
Feb 4, 2009·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·M M WickremaratchiH R Morris
Oct 14, 2011·Neuromodulation : Journal of the International Neuromodulation Society·Young Seok ParkJin Woo Chang
Jul 21, 2015·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Leslie Wayne FergusonAlexander Rajput
Feb 13, 2016·Neurology·Gennaro PaganoNicola Pavese
Dec 13, 2016·Pharmaceutical Biology·Se-Myeong CheonDong Seok Cha
Jan 14, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Mirdhu M WickremaratchiHuw R Morris
Jan 23, 2017·Parkinsonism & Related Disorders·Ali H Rajput, Emma F Rajput
Oct 28, 2017·Archives of Clinical Neuropsychology : the Official Journal of the National Academy of Neuropsychologists·Sarah J Getz, Bonnie Levin
Oct 5, 2014·Journal of Neurology, Neurosurgery, and Psychiatry·Roberto CiliaGianni Pezzoli
Jul 18, 2020·Movement Disorders : Official Journal of the Movement Disorder Society·Yongping ChenHuifang Shang
Jun 7, 2000·Journal of Biomolecular Screening·M H BeydonJ Becquart
Aug 5, 2020·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Connie MarrasTiago A Mestre
Feb 10, 2007·Movement Disorders : Official Journal of the Movement Disorder Society·Ming Chi ShihRodrigo Affonseca Bressan
Oct 22, 2016·Journal of Parkinson's Disease·Alexandre MendesSara Cavaco
Jan 26, 2020·Aging Clinical and Experimental Research·Maria Rita Lo MonacoAnna Rita Bentivoglio
Apr 2, 2021·Frontiers in Human Neuroscience·Edgar PeñaJawad A Bajwa
Apr 4, 2021·Genes·Eun-Mi Hur, Byoung Dae Lee
Mar 10, 2021·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Prashanth L KukkleUNKNOWN Parkinson Research Alliance of India (PRAI)
Sep 7, 2021·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics
Oct 2, 2021·Expert Opinion on Drug Safety·Kanako KuriharaYoshio Tsuboi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
A SchragNiall Quinn
The Journal of Neuroscience Nursing : Journal of the American Association of Neuroscience Nurses
Sharon K Jung
© 2021 Meta ULC. All rights reserved